Navigation Links
Einstein scientists move closer to a safer anthrax vaccine
Date:9/4/2009

September 4, 2009 - (BRONX, NY) - Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

The research is significant because anthrax is considered a major bioterrorism threat. The current anthrax vaccine is intended mainly for members of the armed forces serving in areas considered high risk and for individuals involved in homeland biosecurity.

"Our research was motivated by the fact that the current anthrax vaccine has significant limitations and there is great need for a better one," says lead author Nareen Abboud, Ph.D., an Einstein postdoctoral fellow and lead author of the study, which appears in the current issue of The Journal of Biological Chemistry. The study's senior author is Arturo Casadevall, M.D., Ph.D., Leo and Julia Forchheimer Professor and chairman of microbiology & immunology.

Anthrax, a disease caused by the bacterial species Bacillus anthracis, occurs when anthrax spores (the microbe's dormant stage) are inhaled, ingested or enter the body through an open wound. Anthrax is a common disease among grazing animals such as cows, goats, and sheep but can also result from bioterrorism.

Eighty to 90 percent of people infected through inhalation will die if not treated, according to the U.S. Department of Health and Human Services. In 2001, five people died after inhaling anthrax spores contained in envelopes mailed to U.S. lawmakers and media personnel. Typical treatment post-exposure includes the antibiotics ciprofloxacin, doxycycline and penicillin.

Anthrax results in part from toxic proteins, or toxins, that the multiplying bacteria secrete. The current anthrax vaccine employs one of these proteins, which elicits protective antibodies when injected into people.

While this 40-year-old vaccine can prevent di
'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Einstein researchers devise a fast and sensitive way to detect ricin
2. NIH funds research center for womens reproductive health at Einstein
3. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
4. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
5. Einstein scientists receive $10 million NIH grant
6. Einstein researchers develop technique to count messages made by single genes
7. Einstein researchers develop a new way to study how breast cancer spreads
8. In scientific first, Einstein researchers correct decline in organ function associated with old age
9. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
10. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
11. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Einstein scientists move closer to a safer anthrax vaccine
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... The NIH Neuroscience Microarray Consortium today announced that ... Affymetrix and Illumina platforms to its list of ... says that "adding ultra-high throughput genotyping for its ... the Consortium current with the demands of the ...
... Genetics tests could help provide cystic fibrosis (CF) ... authors suggest. Results from a French clinical trial ... small percentage of CF sufferers with a rare ... , Aleksander Edelman and Isabelle Sermet-Gaudelus of Faculté ...
... good with puzzles or chess, the reason may be in ... psychiatric geneticists at Washington University School of Medicine in St. ... a gene that activates signaling pathways in the brain influences ... the gene, CHRM2, and performance IQ, which involves a person's ...
Cached Biology News:NIH neuroscience microarray consortium launches high-throughput genotyping services 2Genes and genius: Researchers confirm association between gene and intelligence 2Genes and genius: Researchers confirm association between gene and intelligence 3
(Date:6/3/2015)... Photo-Eyewear™ ( http://www.PhotoEyewear.com ) announced ... Inc. ( http://www.PogoTec.com ) to better reflect the ... and technologies it is developing and plans to commercialize. ... PogoTec™ will provide focused resources to drive key areas ... , On-Track™ – There are well over ...
(Date:6/3/2015)... 2015 Global Stem Cells Group ... announced plans to conduct Romania’s first ever stem cells ... alliance with Miami-based Stem Cell Training, Inc., Cosmetic Surgeon ... and Bone Marrow Stem Cell Training Course for medical ... surgery specialist practicing in Bucharest and Tel Aviv, Israel, ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage ... an agreement whereby the institutional investors will have the ... the Company up to $4.93M in near term funding, ... Under the restructured terms and subject to certain market ... could result in a larger influx of capital to ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( ... "Bioburden Testing Market by Product , Test, Application & ... their offering. The bioburden testing market is ... Million in 2014, growing at a CAGR of 9.8% ... products, the microbial limit testing market is segmented into ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... ChemoCentryx, Inc. today announced positive preclinical results for its ... the American Society of Nephrology. CCR2 inhibition in diabetic ... serum markers of renal function, and hyperglycemia.  These data ... Inhibition in Diabetic Mice Results in a Rapid and ...
... Nov. 10, 2011 Sequenom, Inc. (NASDAQ: SQNM ... today announced the Company,s participation at the Lazard Capital Markets ... York City November 15-16, 2011. Harry F. Hixson, ... Director and EVP of Research and Development, will present on ...
... The report " Lung Cancer Drugs ... http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ] " analyzes and studies the major ... Browse in-depth TOC on   ... 2020). Get Free 10% ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 3MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 4
...
... detector for ambient HPLC. Contains connections ... for two external devices such as ... an analog output from the 90 ... recorders. Includes an input for synchronization ...
...
...
Biology Products: